ClinicalTrials.gg
CompletedNCT02126956Updated Apr 30, 2014

Mass Balance, Pharmacokinetics, and Metabolism of 14C-labeled ACT-128800 Administered to Healthy Male Subjects

A Phase 1 interventional study of ACT-128800 in Pharmacokinetics, sponsored by Actelion. Completed at 1 site in Switzerland. Open to male participants aged 45 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-04-30.

Sponsored by Actelion (part of Johnson & Johnson) · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
45 Years to 65 Years
Sex
Male
01

Study summary

The study was conducted to investigate the metabolism and mass balance of ACT-128800, and to identify the elimination pathways (metabolism and excretion) of ACT-128800 and compare them with the known metabolic profiles of ACT-128800 in animals.

02

Conditions studied

  • Pharmacokinetics

Keywords

  • ACT-128800
03

In context

Lead sponsor

Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.

First submitted before Actelion became part of Johnson & Johnson.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signed prior to any study-mandated procedure.
  • Male and aged between 45 and 65 years (inclusive) at screening.
  • No findings on physical examination performed at screening.
  • (BMI) between 18-28 kg/m\^2 (inclusive) at screening.
  • Systolic blood pressure 100-145 mmHg, diastolic blood pressure 50-90 mmHg, and heart rate 55-90 bpm (inclusive), measured on the leading arm, after 5 minutes in the supine position at screening. These criteria should also be met before the administration of the first dose.
  • 12-lead without clinically relevant abnormalities at screening.
  • Clinical chemistry, hematology, and urinalysis results not deviating from the normal range to a clinically relevant extent at screening.
  • Negative results from urine drug screen at screening.
  • Ability to communicate well with the investigator in the local language, and to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  • Known to any of the drug formulation.
  • Treatment with another drug within the 3 months prior to screening.
  • History or clinical evidence of alcoholism or drug abuse within the 3-year period prior to screening.
  • Excessive caffeine consumption, defined as ≥ 800 mg per day at screening.
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition, which might interfere with the absorption, distribution, metabolism or excretion of the study drug.
  • Smoking within the 3 months prior to screening.
  • Any treatment within 6 weeks before study drug administration.
  • Previous treatment with any prescribed or over-the-counter medications (including herbal medicines such as St John's Wort) within 2 weeks prior to screening.
  • Loss of 250 mL or more of blood within the 3 months prior to screening.
  • Lymphopenia (\< 1,100 lymphocytes/μL).
  • Viral, fungal, bacterial or protozoal infection within 4 weeks before study drug administration.
  • Positive or serology, except for vaccinated subjects, at screening.
  • Positive serology at screening.
  • Any circumstances or conditions, which, in the opinion of the investigator, may affect full participation in the study or compliance with the protocol.
  • Legal incapacity or limited legal capacity at screening.
  • Exposure to artificial ionizing radiation (e.g., X-ray, thyroid scan, study with radiolabeled compound) in the 12-month period before screening.
  • A history of constipation (defined as lasting more than 3 days) in the 4-week period before screening.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    ACT-128800

    Subjects received a single oral dose of 40 mg 14C-labeled ACT-128800 (one capsule)

    Drug: ACT-128800

Interventions

  • ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).

06

What researchers measure

Primary outcomes

  1. Cumulative recovery of total radioactivity expressed as a percentage of the administered dose (mass balance) in the urine

    On Day 1, immediately prior to the intake of study drug, subjects were instructed to empty their bladders. Thereafter, following drug intake all urine produced was collected for 10 days up to Day 11 (morning). Following administration of 14C-ACT-128800, urine samples were collected in three consecutive 8-hour intervals, from 0-8 h, 8-16 h, and 16-24 h. From Day 2 to Day 10 (inclusive), urine samples were collected at 24-hour intervals. In case of an extended observation period, urine samples were also collected at 24-hour intervals. The total amount of radioactivity was measured using a liquid scintillation counter.

    Time frame: Up to end of study, approximately 240 hours

  2. Cumulative recovery of total radioactivity expressed as a percentage of the administered dose (mass balance) in the faeces

    Between Day -3 and Day -1, a baseline faeces sample was collected in a light-protected polypropylene box from each subject. From Day 1 (post-dose) to Day 10 (inclusive), all faeces samples and the toilet paper were collected in pre-weighed, light-protected polypropylene boxes. Each faeces sample was collected in a separate box and weighed. The weight of the sample and the time of collection were recorded. All faecal samples were frozen as soon as possible and stored in an upright position at -70 °C or below.The total amount of radioactivity was measured using a liquid scintillation counter.

    Time frame: Up to end of study, approximately 240 hours

Secondary outcomes

  1. Maximum concentration (Cmax) of 14C-radioactivity in whole blood

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity. The amount of radioactivity was measured using a liquid scintillation counter. The measured radioactivity was used to directly obtain Cmax.

    Time frame: Up to end of study, approximately 240 hours

  2. Time to maximum concentration (tmax) of 14C-radioactivity in whole blood

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity. The amount of radioactivity was measured using a liquid scintillation counter. The measured radioactivity was used to directly obtain tmax.

    Time frame: Up to end of study, approximately 240 hours

  3. Area under the plasma concentration-time curve (AUC(0-t)) of 14C-radioactivity in whole blood

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity. The amount of radioactivity was measured using a liquid scintillation counter. AUC(0-t) was calculated according to the linear trapezoidal rule, using the measured concentration-time values above the limit of quantification.

    Time frame: Up to end of study, approximately 240 hours

  4. Area under the plasma concentration-time curve (AUC(0-infinity)) of 14C-radioactivity in whole blood

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity. The amount of radioactivity was measured using a liquid scintillation counter. AUC(0-infinity) was calculated by combining AUC(0-t) and AUC(extra). AUC(extra) represents an extrapolated value obtained by Ct/λz,, where Ct is the last concentration above the limit of quantification and λz, represents the terminal elimination rate constant determined by log-linear regression analysis of the measured concentrations in the terminal elimination phase.

    Time frame: Up to end of study, approximately 240 hours

  5. Half life (t1/2) of 14C-radioactivity in whole blood

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity. The amount of radioactivity was measured using a liquid scintillation counter. t1/2 was calculated as follows: t1/2 = ln 2/λz, where ln 2 is the natural log of 2 (approximately 0.693).

    Time frame: Up to end of study, approximately 240 hours

  6. Maximum concentration (Cmax) of 14C-radioactivity in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity. The amount of radioactivity was measured using a liquid scintillation counter. The measured radioactivity was used to directly obtain Cmax.

    Time frame: Up to end of study, approximately 240 hours

  7. Time to maximum concentration (tmax) of 14C-radioactivity in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity. The amount of radioactivity was measured using a liquid scintillation counter. The measured radioactivity was used to directly obtain tmax.

    Time frame: Up to end of study, approximately 240 hours

  8. Area under the plasma concentration-time curve (AUC(0-t)) of 14C-radioactivity in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity. The amount of radioactivity was measured using a liquid scintillation counter. AUC(0-t) was calculated according to the linear trapezoidal rule, using the measured concentration-time values above the limit of quantification.

    Time frame: Up to end of study, approximately 240 hours

  9. Area under the plasma concentration-time curve (AUC(0-infinity)) of 14C-radioactivity in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity. The amount of radioactivity was measured using a liquid scintillation counter. AUC(0-infinity) was calculated by combining AUC(0-t) and AUC(extra). AUC(extra) represents an extrapolated value obtained by Ct/λz,, where Ct is the last concentration above the limit of quantification and λz, represents the terminal elimination rate constant determined by log-linear regression analysis of the measured concentrations in the terminal elimination phase.

    Time frame: Up to end of study, approximately 240 hours

  10. Half life (t1/2) of 14C-radioactivity in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.0 mL was used for measurement of radioactivity.The amount of radioactivity was measured using a liquid scintillation counter. t1/2 was calculated as follows: t1/2 = ln 2/λz, where ln 2 is the natural log of 2 (approximately 0.693).

    Time frame: Up to end of study, approximately 240 hours

  11. Maximum concentration (Cmax) of ACT-12880 in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.7 mL was used for measurement of ACT-12880 concentration. The concentration of ACT-128800 was determined using a validated liquid chromatography-tandem mass spectrometry assay was used to directly obtain Cmax.

    Time frame: Up to end of study, approximately 240 hours

  12. Time to maximum concentration (tmax) of ACT-12880 in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.7 mL was used for measurement of ACT-12880 concentration. The concentration of ACT-128800 was determined using a validated liquid chromatography-tandem mass spectrometry assay was used to directly obtain tmax.

    Time frame: Up to end of study, approximately 240 hours

  13. Area under the plasma concentration-time curve (AUC(0-t)) of ACT-12880 in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.7 mL was used for measurement of ACT-12880 concentration. The concentration of ACT-128800 was determined using a validated liquid chromatography-tandem mass spectrometry assay . AUC(0-t) was calculated according to the linear trapezoidal rule, using the measured concentration-time values above the limit of quantification.

    Time frame: Up to end of study, approximately 240 hours

  14. Area under the plasma concentration-time curve (AUC(0-infinity)) of ACT-12880 in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.7 mL was used for measurement of ACT-12880 concentration. The concentration of ACT-128800 was determined using a validated liquid chromatography-tandem mass spectrometry assay . AUC(0-infinity) was calculated by combining AUC(0-t) and AUC(extra). AUC(extra) represents an extrapolated value obtained by Ct/λz,, where Ct is the last concentration above the limit of quantification and λz, represents the terminal elimination rate constant determined by log-linear regression analysis of the measured concentrations in the terminal elimination phase.

    Time frame: Up to end of study, approximately 240 hours

  15. Half life (t1/2) of ACT-12880 in plasma

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.7 mL was used for measurement of ACT-12880 concentration. The concentration of ACT-128800 was determined using a validated liquid chromatography-tandem mass spectrometry assay . t1/2 was calculated as follows: t1/2 = ln 2/λz, where ln 2 is the natural log of 2 (approximately 0.693).

    Time frame: Up to end of study, approximately 240 hours

  16. Total lymphocyte count

    Blood samples were collected from an antecubital vein by direct venipuncture or via an intravenous catheter at various time points up to the end of study. An aliquot of 2.7 mL was used for measurement of lymphocyte count

    Time frame: Up to end of study, approximately 240 hours

  17. Change in systolic blood pressure from baseline up to end of study

    Blood pressure was measured at various time points up to the end of study using an automatic oscillometric device. Measurements were taken with the subject in the supine position after a resting period of at least 5 minutes. The leading (writing) arm was used for all blood pressure measurements.

    Time frame: Up to end of study, approximately 240 hours

  18. Change in diastolic blood pressure from baseline up to end of study

    Blood pressure was measured at various time points up to the end of study using an automatic oscillometric device. Measurements were taken with the subject in the supine position after a resting period of at least 5 minutes. The leading (writing) arm was used for all blood pressure measurements.

    Time frame: Up to end of study, approximately 240 hours

  19. Change in heart rate from baseline up to end of study

    Heart rate was measured at various time points up to the end of study using an automatic oscillometric device. Measurements were taken with the subject in the supine position after a resting period of at least 5 minutes. The leading (writing) arm was used for all blood pressure measurements.

    Time frame: Up to end of study, approximately 240 hours

  20. Change in body temperature from baseline up to end of study

    Body temperature was measured at various time points up to the end of study.

    Time frame: Up to end of study, approximately 240 hours

  21. Change in body weight from baseline to end of study

    Body weight was measured at baseline and at end of study using the same weighing scales for all subjects. The weighing scales had a precision of at least 0.5 kg.

    Time frame: Up to end of study, approximately 240 hours

07

Study locations

1 site
  • Swiss Pharma Contract
    Allschwil, Switzerland
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2009, a primary completion of Apr 2009 and a completion of Apr 2009. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2014
First posted
Apr 30, 2014
Start
Mar 2009
Primary completionActual
Apr 2009
CompletionActual
Apr 2009
Last update
Apr 30, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02126956
Lead sponsor
Actelion
Responsible party
Sponsor
First posted
Apr 30, 2014
Start date
Mar 2009
Primary completion
Apr 2009
Completion
Apr 2009
Last update
Apr 30, 2014

Study contacts

Patrick Brossard, PhD
study director · Actelion

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ponesimod

Start the discussion